Jlohr Brain Health
  • Home
  • About Us
  • Brain Health Diagnoses
  • Resources on this Site
    • Overviews: 9 Aspects of this Diagnoses
    • Drug Discount Services
    • With Each Diagnosis:
      • YouTube Video
      • Book from Library or Amazon
      • Support Group or Service
    • Tables for Patients:
      • Possible Special Education
      • Possible Social Security Disability Income
      • School Aid
    • Tables for Patients or Professionals
      • Overview of 9 Aspects of this Diagnosis
      • First Pages of Diagnoses from the Diagnostic and Statistical Manual and the Codes from the ICD-10 for Diagnosis and Compensation
  • Medical & Educational Downloads
  • Contact Us
Select Page

Novel Azepinoindoles as 5-HT2C Agonists for Treating Depression, Drug Addiction, Alcoholism, PTSD, and Neuropathic Pain

by jlohrconsulting | Aug 20, 2025 | Uncategorized

ACS Med Chem Lett. 2025 Jul 28;16(8):1507-1508. doi: 10.1021/acsmedchemlett.5c00426. eCollection 2025 Aug 14. ABSTRACT Provided herein are novel azepinoindoles as 5-HT2C agonists, pharmaceutical compositions, use of such compounds in treating depression, drug...

Novel Non-hallucinogenic Neurite Growth Compounds as 5-HT2A Agonists for Treating Stress-Related Disorders, Namely Depression, Anxiety, and PTSD

by jlohrconsulting | Aug 20, 2025 | Uncategorized

ACS Med Chem Lett. 2025 Jul 30;16(8):1524-1525. doi: 10.1021/acsmedchemlett.5c00440. eCollection 2025 Aug 14. ABSTRACT Provided herein are novel non-hallucinogenic neurite growth compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in...

Novel 3-(2-(Aminoethyl)-indol-4-ol Derivatives as 5-HT2C Agonists for Treating Depression, Alcoholism, Drug Addiction, PTSD, and Seizure Disorders

by jlohrconsulting | Aug 20, 2025 | Uncategorized

ACS Med Chem Lett. 2025 Jul 17;16(8):1503-1504. doi: 10.1021/acsmedchemlett.5c00415. eCollection 2025 Aug 14. ABSTRACT Provided herein are novel 3-(2-(aminoethyl)-indol-4-ol derivatives as 5-HT2C agonists, pharmaceutical compositions, use of such compounds in treating...

Proline Homologation in Melanostatin Neuropeptide: Discovery of Potent Modulators of the Dopamine D2 Receptors

by jlohrconsulting | Aug 20, 2025 | Uncategorized

ACS Med Chem Lett. 2025 Jul 24;16(8):1437-1444. doi: 10.1021/acsmedchemlett.5c00287. eCollection 2025 Aug 14. ABSTRACT Melanostatin (MIF-1) is a naturally occurring neuropeptide acting as a positive allosteric modulator (PAM) of dopamine D2 receptors (D2R),...

Multi-target approach of Egyptian leek extract in ameliorating depressive-like behavior in rats exposed to chronic unpredictable mild stress

by jlohrconsulting | Aug 20, 2025 | Uncategorized

Front Pharmacol. 2025 Aug 4;16:1621762. doi: 10.3389/fphar.2025.1621762. eCollection 2025. ABSTRACT INTRODUCTION: Depression is a widespread and debilitating disorder with a complex etiology involving oxidative stress, neuroinflammation, and apoptosis. Given the...
« Older Entries
Next Entries »

Recent Posts

  • Dissociative Drug-Induced Anxiety
  • Associations in intentions to use anabolic-androgenic steroids among non-consuming boys and men with probable eating disorders and muscle dysmorphia
  • Assessing schema modes for eating disorders and their association with personality traits: validation of the English version of the short form of the schema modes inventory for eating disorders (EN-SMI-ED-SF)
  • Associations in intentions to use anabolic-androgenic steroids among non-consuming boys and men with probable eating disorders and muscle dysmorphia
  • Assessing schema modes for eating disorders and their association with personality traits: validation of the English version of the short form of the schema modes inventory for eating disorders (EN-SMI-ED-SF)

Recent Comments